来自Medicago Sativa L.的中性多糖体:结构性质和低血糖活性在体外和体外
1Bioscience and Biotechnology College, Shenyang Agriculture University, 120 Dongling Road, Shenyang, 10866, PR China.
Chemistry & biodiversity
|August 8, 2024
概括
梅迪卡戈 (Medicago sativa) 的多糖 (MSP) 显示出控制血糖的潜力. 在研究中,一种特定的化合物MSP-II-a增强了葡萄糖吸收和改善了胰岛素抵抗.
科学领域:
- 植物化学 植物化学
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 梅迪卡戈种子的多糖 (MSP) 具有各种药用特性.
- 没有充分了解MSP的低血糖效应.
- 对代谢障碍的新生物活性化合物的研究至关重要.
研究的目的:
- 从Medicago sativa中分离和表征一种特定的多糖 (MSP-II-a).
- 为了评估MSP-II-a在体外和体内低血糖的影响.
- 探索MSP-II-a作为糖尿病的潜在治疗剂.
主要方法:
- 从Medicago sativa中分离和净化MSP-II-a.
- 单糖的组成,结构分析 (甲基化,FTIR,SEM).
- 在3T3-L1脂肪细胞中的体外葡萄糖吸收测定和在糖尿病小鼠中的体内研究.
主要成果:
- 描述了MSP-II-a,一种中性多糖化物 (Mw 4.3×104 Da).
- MSP-II-a含有阿拉伯糖,葡萄糖,银河糖,曼诺糖,拉姆诺糖和西洛糖,具有特定的葡萄糖酸链接.
- 在体内,MSP-II-a促进了葡萄糖的摄取,并减轻了胰岛素抵抗.
结论:
- MSP-II-a表现出显著的低血糖活性.
- 该化合物显示出治疗胰岛素抵抗和糖尿病的潜力.
- 麦当劳草是一种有价值的生物活性多糖的来源,用于治疗应用.
更多相关视频
12:02Automated Modular High Throughput Exopolysaccharide Screening Platform Coupled with Highly Sensitive Carbohydrate Fingerprint Analysis
Published on: April 11, 2016
11.5K
10:26Author Spotlight: Integrating Biochemical Functions of β-Glucanases and Peroxidase Enzymes in Wheat-RWA Interaction
Published on: July 26, 2024
635
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
168
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
168
Oral Hypoglycemic Agents: Glinides
150
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
150
Oligosaccharide Assembly
2.8K
Protein glycosylation starts in the ER lumen and continues in the Golgi apparatus. Glycosyltransferases catalyze the addition of sugar molecules or glycosylation of proteins. Usually, these enzymes add sugars to the hydroxyl groups of selected serine or threonine residues to form O-linked glycans or the amino groups of asparagine residues to form N-linked glycans. Different positions on the same polypeptide chain can contain differently linked glycans.
Multiple sugar molecules that may or may...
Multiple sugar molecules that may or may...
2.8K
Hypoglycemia and Glucagon
224
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
224
Glucagon-like Receptor Agonists
311
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
311
Overview of Carbohydrate Metabolism
833
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
833
